Companies Report Corporate Growth and Positive Clinical Data - Research Report on Humana, Molina Healthcare, Novavax, Kindred Healthcare, and Repligen
NEW YORK, November 27, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Humana Inc. (NYSE: HUM), Molina Healthcare Inc. (NYSE: MOH), Novavax, Inc. (NASDAQ: NVAX), Kindred Healthcare Inc. (NYSE: KND), and Repligen Corporation (NASDAQ: RGEN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Humana Inc. Research Report
On November 22, 2013, Humana Inc.'s (Humana) stock was up by 1.53% as it closed at $101.25 per share. Over the past three trading day period, Humana's stock went up by 2.65%, compared to the Dow Jones Industrial Average which went up by 0.61% during the same trading period. The Full Research Report on Humana Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/496b_HUM
--
Molina Healthcare Inc. Research Report
On November 22, 2013, Molina Healthcare Inc.'s (Molina Healthcare) stock closed at $32.75 per share, reflecting an increase of 3.64% upon closing. Molina Healthcare's stock was up by 3.94% over the previous three trading day period, compared to the S&P 500 which went up by 0.94% over the same trading period. The Full Research Report on Molina Healthcare Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/1a59_MOH
--
Novavax, Inc. Research Report
On November 13, 2013, Novavax, Inc. (Novavax) announced that the Company's virus-like particle (VLP) vaccine candidate against A(H7N9) influenza was published online with positive clinical data in the Correspondence section of The New England Journal of Medicine, and will appear in print edition of December 26, 2013. Commenting on the release, Dr. Lou Fries, Company Vice President of Clinical and Medical Affairs, stated, "The production and testing of a vaccine for a novel, lethal influenza virus in such a short time period validates the agility of Novavax' technology in addressing pandemic threats. The performance of our vaccine candidate is particularly important in light of the speed with which pandemic outbreaks can unfold. Often, an initial outbreak of a novel influenza virus is followed by a more severe and widespread outbreak at the onset of the next fall and winter respiratory virus season, as seen in 2009 with H1N1. Unfortunately, vaccine makers in 2009 were unable to produce vaccine in advance of the second wave and there was little impact of vaccine upon H1N1 disease in the first year. Past H7-based vaccine candidates have been poorly immunogenic and thus could not be advanced as viable vaccine candidates. This risk appears to have been overcome by
our H7N9 adjuvanted VLP vaccine." The Full Research Report on Novavax, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/bc35_NVAX
--
Kindred Healthcare Inc. Research Report
On November 22, 2013, Kindred Healthcare Inc.'s (Kindred Healthcare) stock was up by 1.93% as it closed the day at $16.39 per share. Over the previous three-day trading period, Kindred Healthcare's stock was up by 4.20%, compared to the Dow Jones Industrial Average which went up by 0.61% over the same trading period. The Full Research Report on Kindred Healthcare Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/ab58_KND
--
Repligen Corporation Research Report
On November 19, 2013, Repligen Corporation (Repligen) announced that it has elected John G. Cox, Executive Vice President of Pharmaceutical Operations & Technology for Biogen Idec Inc. to the Company's Board of Directors. Walter C. Herlihy, Ph.D., President and CEO of Repligen, stated, "Mr. Cox's experience and his perspective as an end user of the products developed and marketed by Repligen make him ideally suited to provide strategic guidance to our Company, and we are pleased to welcome him as an important addition to our Board. We also sincerely thank Dr. Henry for his many contributions to Repligen; in particular, his medical expertise was invaluable while the Company was active in the clinical development of therapeutics." The Full Research Report on Repligen Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/fdda_RGEN
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
Share this article